In a phase II study, EscharEx demonstrated safe and effective debridement of diabetic foot ulcers and venous leg ulcers.
A phase II pharmacology study has found positive initial data of EscharEx, a bioactive therapy for rapid debridement in chronic and hard-to-heal wounds, Israeli biopharmaceutical company MediWound announced on Monday … The US-based study, which is ongoing, examined the treatment of seven patients with either diabetic foot ulcers (DFUs) or venous leg ulcers (VLUs) … read more